Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Comment by holliganzon Mar 22, 2024 9:43am
222 Views
Post# 35946833

RE:Bought deal RAISES questions. Why now?

RE:Bought deal RAISES questions. Why now?the insider your referring to that sold was a director exercising stock options that were expiring. They only had enough cash for this trial. If the trial is successful they have fast track designation from the FDA and will immediately start a trial for drug approval. The offering is with close tied underwriters and insiders
“Certain insiders of the Company, led by an entity associated with PFP Biosciences, the largest inside shareholder who invested US$15 million in 2022, as well as a majority of the Company's executives and board members are expected to participate in the Offering.”

Make what you want of it. Best of luck
Cheers

<< Previous
Bullboard Posts
Next >>